Aethlon Medical, Inc. (AEMD)
$
0.36
-0.01 (-2.78%)
Key metrics
Financial statements
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aethlon Medical, Inc., a medical technology enterprise dedicated to addressing life-threatening diseases, has reported an income tax expense of $3.00 indicating its tax obligations. The company's operational overhead is reflected in the selling, general, and administrative expenses of $9,757,511.00. As part of its financial data, the weighted average number of diluted shares outstanding is 2,512,774.00 which shows the potential dilution effects for shareholders. Furthermore, the company has recognized depreciation and amortization expenses of $359,057.00 indicative of the wear and tear on its assets. Aethlon Medical achieved a revenue of $0.00 highlighting its focus on niche markets within the healthcare landscape. Aethlon’s flagship product, the Aethlon Hemopurifier, is an advanced clinical-stage immunotherapeutic device aimed at removing harmful tumor-derived exosomes and life-threatening viruses, including SARS-CoV-2 and its variants, demonstrating the company’s commitment to innovative medical solutions. Collaborating with the University of Pittsburgh Medical Center Hillman Cancer Center, Aethlon is actively involved in studies aimed at improving outcomes in head and neck cancer, further underscoring its strategic partnerships and research endeavors. The stock is affordable at $0.36 making it an attractive option for budget-conscious investors. With a high average trading volume of 683,205.00 the stock demonstrates strong liquidity, appealing to those looking for active trading opportunities. Aethlon Medical has a market capitalization of $7,395,242.00 classifying it as a small-cap player in the competitive landscape. It is a key player in the medical technology industry, contributing significantly to the overall market landscape by focusing on innovative products and therapies. Moreover, it belongs to the Healthcare sector, driving innovation and growth while addressing critical healthcare needs. Through its efforts, Aethlon Medical continues to position itself as a vital contributor in the quest for advanced medical solutions, reflecting its strategic vision and dedication to improving patient care.
Is Aethlon Medical, Inc. (AEMD) a good investment?
Investing in Aethlon Medical, Inc. (AEMD) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Aethlon Medical, Inc. (AEMD)'s stock forecast?
Analysts predict Aethlon Medical, Inc. stock to fluctuate between $0.24 (low) and $1.79 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aethlon Medical, Inc.'s market capitalization?
As of 2025-04-02, Aethlon Medical, Inc.'s market cap is $7,395,242, based on 20,657,100 outstanding shares.
How does Aethlon Medical, Inc. compare to competitors like Apple Inc.?
Compared to Apple Inc., Aethlon Medical, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aethlon Medical, Inc. (AEMD) stock?
To buy Aethlon Medical, Inc. (AEMD) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AEMD. Place an order (Market, Limit, etc.).
What is the best time to invest in Aethlon Medical, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Aethlon Medical, Inc. stock ever split?
Aethlon Medical, Inc.'s last stock split was 1:10 on 2023-10-05.
How did Aethlon Medical, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$4.86 | Growth: -17.06%.
Where can I find Aethlon Medical, Inc.'s investor relations reports?
Visit https://www.aethlonmedical.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aethlon Medical, Inc.?
You can explore historical data from here
What is the all-time high and low for Aethlon Medical, Inc. stock?
All-time high: $124.90 (2021-06-09) | All-time low: $0.24 (2024-08-05).
What are the key trends affecting Aethlon Medical, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Aethlon Medical, Inc. (NASDAQ:AEMD ) Q3 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Jim Frakes – Chief Executive Officer Steven LaRosa – Chief Medical Officer Conference Call Participants Marla Marin – Zacks Anthony Vendetti – Maxim Group Operator Good day, and welcome to the Aethlon Medical Third Quarter Fiscal 2025 Earnings and Corporate Update Call. All participants will be in a listen-only mode.
prnewswire.com
SAN DIEGO , Feb. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2024, at 4:15 p.m. ET on Wednesday, February 12, 2025.
prnewswire.com
First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Jan. 29, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the first patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study).
prnewswire.com
SAN DIEGO , Dec. 20, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu." Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the treatment of Bird Flu.
newsfilecorp.com
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 14, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases a snapshot looking at the advancement of treatments for solid tumors as global cancer incidence rates rise, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. According to a recent article in Biospace,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023.
seekingalpha.com
Aethlon Medical, Inc. (NASDAQ:AEMD ) Q2 2025Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations, Rx Communications James Frakes - Interim Chief Executive Officer & Chief Financial Officer Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Jeremy Pearlman - Maxim Group Operator Good day, and welcome to the Aethlon Medical Fiscal Second Quarter 2025 Earnings and Corporate Update. [Operator Instructions] Please note this event is being recorded.
prnewswire.com
Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies Two Australian Sites Open For Patient Enrollment in Hemopurifier® Cancer Trial Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Nov. 13, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2024 and provided an update on recent developments.
newsfilecorp.com
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - November 12, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical technology as first patients are enrolled in potential breakthrough trials, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/11120AEMD-First-Patient-Enrollments.asp According to Statista.com, "The Medical Technology market, which encompasses various markets, including Medical Devices, is anticipated to witness significant revenue growth in the coming years.
prnewswire.com
Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Nov. 11, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof.
prnewswire.com
SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2024, at 4:15 p.m. ET on Wednesday, November 13, 2024.
See all news
